Betulinic Acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Betulinic Acid
DrugBank Accession Number
DB12480
Background

Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 456.711
Monoisotopic: 456.360345406
Chemical Formula
C30H48O3
Synonyms
  • beta-betulinic acid
External IDs
  • ALS-357
  • NSC-113090

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Betulinic Acid.
AcemetacinThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betulinic Acid.
AlclofenacThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Alclofenac.
AminophenazoneThe risk or severity of adverse effects can be increased when Aminophenazone is combined with Betulinic Acid.
AmitriptylineThe risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Betulinic Acid.
AmitriptylinoxideThe risk or severity of gastrointestinal bleeding can be increased when Amitriptylinoxide is combined with Betulinic Acid.
AmoxapineThe risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Betulinic Acid.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betulinic Acid.
AntrafenineThe risk or severity of adverse effects can be increased when Antrafenine is combined with Betulinic Acid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
EpisalvanBetulinic Acid (80 mg/1g) + Birch bark extract (100 mg/1g)GelCutaneousAmryt Ag2021-02-10Not applicableEU flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Triterpenoids
Direct Parent
Triterpenoids
Alternative Parents
18-hydroxysteroids / Oxosteroids / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
18-hydroxysteroid / 18-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Cyclic alcohol / Hydrocarbon derivative / Hydroxysteroid
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
hydroxy monocarboxylic acid, pentacyclic triterpenoid (CHEBI:3087) / Lupanes (C08619) / Lupane triterpenoids (LMPR0106140004)
Affected organisms
Not Available

Chemical Identifiers

UNII
4G6A18707N
CAS number
472-15-1
InChI Key
QGJZLNKBHJESQX-FZFNOLFKSA-N
InChI
InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
IUPAC Name
(1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-17-hydroxy-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0²,¹⁰.0⁵,⁹.0¹⁴,¹⁹]henicosane-5-carboxylic acid
SMILES
[H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2

References

General References
Not Available
Human Metabolome Database
HMDB0030094
KEGG Compound
C08619
PubChem Compound
64971
PubChem Substance
347828718
ChemSpider
58496
BindingDB
23208
ChEBI
3087
ChEMBL
CHEMBL269277
ZINC
ZINC000004097714

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentEpidermolysis Bullosa (EB)1
3CompletedTreatmentWound site2
1Unknown StatusTreatmentMalignant Melanoma of Skin1
1, 2WithdrawnTreatmentDysplastic Nevus Syndrome1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
GelCutaneous
GelTopical80 mg/g
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000204 mg/mLALOGPS
logP5.34ALOGPS
logP6.64ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)4.75ChemAxon
pKa (Strongest Basic)-0.84ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity132.63 m3·mol-1ChemAxon
Polarizability54.64 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0019400000-d634f687c0b20b3bf518
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0019400000-946b3acbf03ebc325984
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-06vi-0009700000-133d884e7fe1aabfb659
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-06vr-0019800000-a2c226a96551460f31b8
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0000411190-9e794d71d8e215a3ef7f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0000511290-00b42fd32f4bea1aac24
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0009100000-02c4ffe35137e2459ef9
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0009100000-b369b92782bf0058f776
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-31877b3328749253f478
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-46226c91dca257ecbdbe
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0119300000-d165dda7f84c911bb084
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-004i-0119400000-c8efa7eb386af139bbbb
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-5daf110b6535ef5e1cba
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0udi-0000900000-1a6ea554c157db014b7c
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-01p9-0000900000-95cc62b5cf4bd28b6108
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-01p9-0000900000-1a328cc168bc37caf6d7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4r-0920300000-e3035523b40f714793c7

Drug created on October 20, 2016 22:33 / Updated on March 03, 2021 21:57